이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Adial Pharmaceuticals 관리

관리 기준 확인 4/4

Adial Pharmaceuticals' CEO는 Cary Claiborne, Aug2022 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 $ 801.62K, 58.1% 로 구성됩니다. 58.1% 급여 및 41.9% 보너스(회사 주식 및 옵션 포함). 는 $ 77.21K 가치에 해당하는 회사 주식의 1.44% 직접 소유합니다. 77.21K. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 6.9 년입니다.

주요 정보

Cary Claiborne

최고 경영자

US$801.6k

총 보상

CEO 급여 비율	58.1%
CEO 임기	1.8yrs
CEO 소유권	1.4%
경영진 평균 재임 기간	3.4yrs
이사회 평균 재임 기간	6.9yrs

최근 관리 업데이트

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

CEO 보상 분석

Cary Claiborne 의 보수는 Adial Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$802k	US$466k	-US$7m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$1m	US$357k	-US$11m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$16m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$688k	US$15k	-US$19m

보상 대 시장: Cary 의 총 보상 ($USD 801.62K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Cary 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Cary Claiborne (63 yo)

1.8yrs

테뉴어

US$801,621

보상

Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...

리더십 팀

이름	위치	테뉴어	보상	소유권
Cary Claiborne	CEO, President & Director	1.8yrs	US$801.62k	1.44% $ 66.9k
Joseph A. Truluck	CFO, Treasurer & Secretary	7yrs	US$389.03k	0.25% $ 11.7k
John Martin	Chief Legal Officer	3.4yrs	데이터 없음	데이터 없음
Catherine Fratila	Controller	3.4yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

경험이 풍부한 관리: ADIL 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Cary Claiborne	CEO, President & Director	2.6yrs	US$801.62k	1.44% $ 66.9k
Kevin Schuyler	Chairman & Lead Independent Director	8.2yrs	US$60.22k	0.16% $ 7.3k
James Newman	Independent Director	9.8yrs	US$56.22k	0.32% $ 14.9k
Robertson Gilliland	Independent Director	9.8yrs	US$53.22k	0% $ 0
J. Anderson	Independent Director	9.3yrs	US$59.22k	0% $ 0
Giovanni Addolorato	Chairperson of Scientific Advisory Board	5.6yrs	데이터 없음	데이터 없음
Tomáš Zima	Member of the Scientific Advisory Board	5.4yrs	데이터 없음	데이터 없음
Sebastian Mueller	Member of Scientific Advisory Board	5.4yrs	데이터 없음	데이터 없음

6.9yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: ADIL 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.

Adial Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Independent Director recently bought US$67k worth of stock

Recent updates

Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $4.28365 million.

Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding

Price target decreased by 19% to US$21.00

New major risk - Share price stability

Price target decreased by 17% to US$17.00

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Adial Pharmaceuticals, Inc. announced delayed amended 10-Q filing

Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding

Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding

Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals, Inc. announced delayed 10-Q filing

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

New major risk - Share price stability

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Compliance with Nasdaq Listing Rule 5550(b)(1)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Adial Clinical Trial: A Fluff Or A Win?

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial

Price target increased to US$10.67

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Independent Director recently bought US$67k worth of stock

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc.

Chairman recently bought US$55k worth of stock

Adial Pharmaceuticals, Inc. Announces Positive Pre-Clinical Data for PNV2 as A Drug Candidate for Triple Negative Breast Cancer

Director William Stilley has joined 3rd company board

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding from Bespoke Growth Partners, Inc., Keystone Capital Partners LLC

Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Adial Pharmaceuticals, Inc. announced that it has received $2.100003 million in funding from Keystone Capital Partners LLC, Bespoke Growth Partners, Inc., Rountop Limited Partnership, LLP and another investor

Forecast breakeven pushed back to 2024

Adial Pharmaceuticals Achieves 50% Enrollment in landmark ONWARD™ Phase 3 Trial

Adial Pharmaceuticals, Inc. to File Fast Track Application for Ad04 with the FDA

New 90-day high: US$3.19

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) completed the acquisition of Purnovate, LLC from the members of Purnovate.

New 90-day high: US$2.34

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) entered into an Equity Purchase Agreement to acquire Purnovate, LLC from the members of Purnovate.

Adial Pharmaceuticals, Inc. Announces Management and Board Changes, Effective December 14, 2020

Adial Pharmaceuticals, Inc. announced that it expects to receive funding from Keystone Capital Partners LLC

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Adial Pharmaceuticals, Inc. Announces That U.S. Food and Drug Administration Issues an Emergency Use Authorization for the Assure/Fastep® Covid-19 Igg/Igm Rapid Test Device

Adial Pharmaceuticals, Inc. Files for Expedited Review of AD04 with the FDA

Adial Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Bespoke Growth Partners, Inc.

New 90-day low: US$1.21

Adial Pharmaceuticals, Inc. and Iremedy Healthcare Companies, Inc. Partner to Sell Covid-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales

New 90-day low - US$1.32

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀